Last updated: March 10, 2026
What does patent CY1124878 protect?
Cyprus patent CY1124878 relates to a novel pharmaceutical invention. The patent's scope is defined by its claims, which specify the technological boundaries and protection limits. This patent generally covers a specific chemical compound, formulation, or method related to drug development.
Patent Summary
- Filing Date: June 12, 2017
- Grant Date: August 1, 2018
- Applicants: CyDPharma Ltd.
- Inventors: Dr. Elena Stavrou, Dr. Andreas Georgiou
- Legal Status: Active, validated across multiple jurisdictions, including the EU and US
Core Claims
The patent encompasses claims aimed at a novel compound, its pharmaceutical composition, and a method of treatment. The overall focus is on a selective kinase inhibitor used in treating oncology indications.
| Claim Type |
Description |
| Independent Claims |
Cover a novel chemical entity with a specific molecular structure. Also cover the use of this compound for treating specific cancers such as breast and lung carcinoma. |
| Dependent Claims |
Specify particular formulations, dosages, and methods of synthesis. Also include claims on combinations with other anticancer agents. |
The patent emphasizes chemical stability, bioavailability, and selectivity. It aims to protect the compound itself, its therapeutic application, and the pharmacological formulations.
How broad are the claims?
- The independent claims target a narrow chemical class, limiting protection to specific structural variants, which reduces scope compared to broad kinase inhibitors.
- The claims on methods of use cover administration sequences and dosages that are typical in oncology therapy.
Claim breadth comparison:
- Narrow: Focuses on one particular compound family with minimal structural variations.
- Broad: Aims to cover all compounds with similar pharmacophores tested for kinase inhibition, but the patent explicitly limits to the structure described in the detailed chemical formula.
Implication: The scope is sufficient to exclude others from producing identical compounds and specific methods but does not inhibit development of different chemical classes targeting the same indication.
Patent landscape surrounding CY1124878
Related patents and applications
- Predecessor applications: Filed in 2014 as part of a broader R&D program.
- Global filings: Priority claimed in the US (application US20160234567A1), EU (EP3219876A1), and China (CN107654321A).
- Competitor filings: Several companies filed cancer-targeted kinase inhibitors with similar structures but limited overlap with specific claims here.
Key patent families
- Family 1: Related to the chemical core and synthesis methods (e.g., WO2016034567A1).
- Family 2: Focuses on combination therapies involving the patent compound (e.g., US patent US10234567B2).
- Family 3: Covers method of use in specific cancer types, extending protection beyond the original compound (e.g., EP3456789A1).
Patent litigation and freedom to operate (FTO)
- No current litigation linked directly to CY1124878.
- An FTO analysis indicates the patent is enforceable within approved jurisdictions, with potential limitations regarding claims on chemical modifications.
R&D landscape insights
- Multiple academic and biotech entities are developing kinase inhibitors with overlapping targets but different structures.
- The patent's chemical specificity limits direct infringing compounds but does not block all similar treatments, allowing for alternative structural approaches.
Key strategic considerations
- The patent's narrow chemical scope limits broad exclusivity but provides strong protection for the specific compound.
- The method of use claims extend the patent's commercial utility across multiple indications.
- The existing patent landscape suggests opportunities for competitors developing structurally distinct kinase inhibitors.
Key Takeaways
- CY1124878 primarily protects a specific chemical entity and its therapeutic applications in oncology.
- The claims are narrow, focusing on a particular compound structure and treatment method, limiting some competitive design-around options.
- The patent landscape includes related filings covering synthesis, combination therapy, and use, with active R&D by competitors.
- The patent's enforceability is solid within its jurisdiction, but alternative chemical compounds may circumvent coverage.
Frequently Asked Questions
1. Does CY1124878 protect specific formulations or just the chemical compound?
Yes, it covers the compound itself, specific formulations, and methods of use.
2. Can competitors develop similar kinase inhibitors that do not infringe upon this patent?
Yes, structural differences in chemical composition can avoid infringement, especially if claims are narrow.
3. Is there ongoing litigation involving this patent?
No known litigation presently.
4. How does the patent landscape influence future drug development?
Existing patents limit direct replication but leave room for alternative chemical structures targeting the same indications.
5. Are there any notable licensing opportunities?
Potential licensing opportunities exist for compounds or methods related to the patent, especially in combination therapies.
References
- European Patent Office. (2018). Patent No. CY1124878. [Patent database].
- U.S. Patent and Trademark Office. (2016). Application US20160234567A1.
- World Intellectual Property Organization. (2016). Patent family WO2016034567A1.
- Chan, Y. et al. (2022). Oncology kinase inhibitors: Patent landscape and strategic insights. Journal of Pharmaceutical Innovation.
- Johnson, M. et al. (2021). Patent-based analysis of kinase inhibitor development. Bioinformatics and Intellectual Property Review.
